Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 366 matching drugs for CALR — including drugs targeting any of its 83 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
disulfiram, copper, alkylating agents CALR Direct 1
omeprazole, melatonin CALR Direct 1
adagrasib KRAS SSL via KRAS yes 2
sotorasib KRAS SSL via KRAS yes 2
sunitinib KIT SSL via KIT yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab ABL1 SSL via ABL1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) ABL1 SSL via ABL1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ABL1 SSL via ABL1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KIT SSL via KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAP2K1 SSL via MAP2K1 3
afatinib ERBB4 SSL via ERBB4 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
pembrolizumab, belzutifan, lenvatinib KIT SSL via KIT 3
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ABL1 SSL via ABL1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel INSR SSL via INSR 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel MAP2K1 SSL via MAP2K1 2
alendronate, etidronate, ibandronate, risedronate, raloxifene ESR1 SSL via ESR1 2
alvocidib, paclitaxel CDK1 SSL via CDK1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK5 SSL via CDK5 2
avapritinib KIT SSL via KIT yes 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment ABL1 SSL via ABL1 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KIT SSL via KIT 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib MAP2K1 SSL via MAP2K1 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
cft1946, trametinib, cetuximab MAP2K1 SSL via MAP2K1 2
cobimetinib, mehd7945a MAP2K1 SSL via MAP2K1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ESR1 SSL via ESR1 2
gefitinib, fulvestrant, erlotinib ESR1 SSL via ESR1 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KIT SSL via KIT 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib MAP2K1 SSL via MAP2K1 2
lenvatinib, pembrolizumab KIT SSL via KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KIT SSL via KIT 2
mirdametinib, bgb-3245 MAP2K1 SSL via MAP2K1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KIT SSL via KIT 2
nivolumab, ipilimumab, cobimetinib MAP2K1 SSL via MAP2K1 2
palbociclib CDK4 SSL via CDK4 yes 2
pazopanib KIT SSL via KIT yes 2
pembrolizumab, lenvatinib KIT SSL via KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KIT SSL via KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KIT SSL via KIT 2
regorafenib ABL1 SSL via ABL1 yes 2
regorafenib KIT SSL via KIT yes 2
regorafenib, laboratory biomarker analysis ABL1 SSL via ABL1 2
regorafenib, laboratory biomarker analysis KIT SSL via KIT 2
selinexor XPO1 SSL via XPO1 yes 2
selumetinib, medi4736, tremelimumab MAP2K1 SSL via MAP2K1 2
sorafenib, administered orally, ct/mri KIT SSL via KIT 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel ESR1 SSL via ESR1 2
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) MAP2K1 SSL via MAP2K1 1
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK4 SSL via CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine CDK4 SSL via CDK4 1
abemaciclib, ly3214996 CDK4 SSL via CDK4 1
abemaciclib, surgery CDK4 SSL via CDK4 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy CDKN1A SSL via CDKN1A 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy PPARG SSL via PPARG 1
adriamycin, cyclophosphamide, vindesine, valproic acid CDKN1A SSL via CDKN1A 1
adriamycin, cyclophosphamide, vindesine, valproic acid PPARG SSL via PPARG 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ABL1 SSL via ABL1 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CDK4 SSL via CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KIT SSL via KIT 1
afatinib, docetaxel, radiation therapy ERBB4 SSL via ERBB4 1
afatinib, gefitinib ERBB4 SSL via ERBB4 1
afatinib, irinotecan ERBB4 SSL via ERBB4 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib MAP2K1 SSL via MAP2K1 1
alvocidib, docetaxel CDK1 SSL via CDK1 1
alvocidib, docetaxel CDK4 SSL via CDK4 1
alvocidib, docetaxel CDK5 SSL via CDK5 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK1 SSL via CDK1 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK4 SSL via CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK5 SSL via CDK5 1
apalutamide, cetrelimab AR SSL via AR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib CDK4 SSL via CDK4 1
arsenic trioxide CCND1 SSL via CCND1 1
arsenic trioxide CDKN1A SSL via CDKN1A 1
arsenic trioxide JUN SSL via JUN 1
arsenic trioxide, radiation therapy CCND1 SSL via CCND1 1
arsenic trioxide, radiation therapy CDKN1A SSL via CDKN1A 1
arsenic trioxide, radiation therapy JUN SSL via JUN 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy CCND1 SSL via CCND1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy CDKN1A SSL via CDKN1A 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy JUN SSL via JUN 1
atezolizumab, tivozanib KIT SSL via KIT 1
avapritinib, midazolam KIT SSL via KIT 1
bevacizumab, dasatinib, placebo ABL1 SSL via ABL1 1
bevacizumab, dasatinib, placebo KIT SSL via KIT 1
bicalutamide, intensity-modulated radiation therapy (imrt) AR SSL via AR 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.